Engineered RBCs for GAA Breakdown and Creatine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Guanidinoacetate Methyltransferase (GAMT) deficiency, such as high-dose creatine supplementation, suffer from poor patient compliance due to strict adherence requirements, and there is a need for a more effective therapeutic approach to manage the accumulation of toxic guanidinoacetate acid (GAA) and restore creatine levels.
Innovation Solution
Engineering red blood cells (RBCs) to express recombinant guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) proteins, enabling the conversion of GAA into creatine using a modified metabolic pathway, thereby degrading the toxic metabolite and producing creatine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high-dose creatine supplementation is used to treat GAMT deficiency, then creatine levels increase, but patient compliance deteriorates due to strict adherence requirements
Solution Approach 1:
The engineered red blood cells perform the creatine synthesis function autonomously within the patient's body. The cells express functional GAMT and MAT enzymes that automatically convert GAA to creatine without requiring external supplementation or patient adherence to dosing schedules, thus resolving the compliance issue while maintaining therapeutic effect
Solution Approach 2:
The engineered red blood cells serve as intermediary carriers that deliver the therapeutic function directly to the site of need. By introducing cells with the necessary enzymatic machinery into the patient's circulation, the therapy bypasses the need for oral supplementation and achieves continuous creatine production without relying on patient compliance
2Reliability
If conventional enzyme replacement therapy is used, then GAMT deficiency is addressed, but the metabolic pathway remains incomplete and creatine production is insufficient
Solution Approach 1:
The invention combines two essential enzymes (GAMT and MAT) into a single therapeutic cell system. By co-expressing both enzymes in the same red blood cells, the complete metabolic pathway from GAA to creatine is restored, enabling continuous and sufficient creatine production that conventional single-enzyme therapies cannot achieve
Solution Approach 2:
The engineered cells are prepared ex vivo before administration to the patient. The cells are pre-engineered with the correct enzymatic composition and functional integrity, ensuring that upon introduction into the patient's circulation, they immediately begin producing creatine without requiring in vivo adaptation or having incomplete pathway function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered RBCs effectively degrade GAA and produce creatine, addressing the deficiency by maintaining native cell properties and providing a continuous, physiological production of creatine, suitable for treating GAMT deficiency and related conditions.
Implementation Method 1
modified for catalyzing the conversion of guanidinoacetate acid (GAA) into creatine in the presence of glucose and methionine using an exogenous guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) protein
Implementation Method 2
These two enzymes, collectively, activate a new metabolic pathway that permits said isolated cells, such as red blood cells (RBCs) to catabolize GAA with the simultaneous formation of creatine
Data Source
Figure 1~2[C]
Figure 3~4[C]
Figure 5[A]~6[C]
AI summary
The present invention relates to an isolated cell modified for catalyzing the conversion of guanidinoacetate acid (GAA) into creatine in the presence of glucose and methionine using an exogenous guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) protein, a pharmaceutical composition comprising a plurality of said isolated cells and uses thereof.